News

 |  News

Dr. Ragueneau-Majlessi to present at the upcoming AAPS Meeting

Dr. Isabelle Ragueneau-Majlessi, Clinical Professor and Director of the DIDB Program, is an invited speaker at the session entitled “Overcoming potential setbacks? Prediction of Drug-Drug interactions via Computational Modeling“, taking place on Wednesday November 5th (7:00-8:30am) at the AAPS Meeting in San Diego. She will be presenting on “Indexing and Curating Drug-Drug Interaction Data: experience of the University of Washington Drug Interaction Database”.

 |  News

DIDB Team to exhibit at the upcoming ISSX/JSSX Meeting – San Francisco 10/19-10/23, 2014

Please visit the DIDB Team at Booth #408 during this year’s ISSX/JSSX Meeting to be held in San Francisco October 19 -23, 2014.

Also, please come to the following poster presentations:

  • P94 – ASSESSMENT OF THE IMPACT OF RENAL OR HEPATIC IMPAIRMENT VS PHARMACOLOGIC INHIBTION ON SYSTEMIC EXPOSURE OF DRUGS (Cathy Yeung, Makiko Kusama, Huixia Zhang, Isabelle Ragueneau-Majlessi, Sophie Argon, Li Li, Peter Chang, Ping Zhao, Lei Zhang, Kenta Yoshida, Issam Zineh, Yuichi Sugiyama, Shiew-Mei Huang).
  • Monday October 20
  • Presented by Authors: 1:15 – 2:00 pm  (Dr. Cathy Yeung)
  • P173 – DRUG DISPOSITION AND DRUG-DRUG INTERACTION DATA IN 2013 FDA NEW DRUG APPLICATIONS: A SYSTEMATIC REVIEW (Jingjing Yu and Isabelle Ragueneau-Majlessi).
  • Monday October 20
  • Presented by Authors: 4:30-5:15 pm (Dr. Jingjing Yu)
  • P390 – USE OF IN VIVO DISPOSITION DATA TO DETERMINE CYP2D6 PROBE fm VALUES AND DEVELOP PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELS TO PREDICT GENOTYPE DEPENDENT CYP2D6-MEDIATED DRUG-DRUG INTERACTIONS (Mariko Nakano, Jingjing Yu, Sophie Argon, Isabelle Ragueneau-Majlessi, Nina Isoherranen).
  • Tuesday October 21
  • Presented by Authors: 6:15-7:00 pm (Dr. Mariko Nakano)
 |  Publications
Tags: , , , , , , ,

Drug Disposition and Drug-Drug Interaction Data in 2013 FDA New Drug Applications: A Systematic Review

Drug Metab Dispos. 2014 Dec; 42(12); 1991-2001.
Published online 2014 Sep 30

Abstract

The aim of the present work was to perform a systematic review of drug metabolism, transport, pharmacokinetics, and DDI data available in the NDAs approved by the FDA in 2013, using the University of Washington Drug Interaction Database, and to highlight significant findings. Among 27 NMEs approved, 22 (81%) were well characterized with regard to drug metabolism, transport, or organ impairment, in accordance with the FDA drug interaction guidance (2012) and were fully analyzed in this review. In vitro, a majority of the NMEs were found to be substrates or inhibitors/inducers of at least one drug metabolizing enzyme or transporter. However, in vivo, only half (n = 11) showed clinically relevant drug interactions, with most related to the NMEs as victim drugs and CYP3A being the most affected enzyme. As perpetrators, the overall effects for NMEs were much less pronounced, compared with when they served as victims. In addition, the pharmacokinetic evaluation in patients with hepatic or renal impairment provided useful information for further understanding of the drugs’ disposition.

 |  Events

DIDB Team at the 17th International Conference on Drug-Drug Interactions

The DIDB team will be exhibiting at the 17th International Conference on Drug-Drug Interactions in Seattle on June 30-July 2, 2014, and will contribute to the scientific program with two presentations:

* Critical Review of the 2013-2014 Literature (Dr. Sophie Argon)

* New Molecular Entities Approved by FDA in 2013: Review of In Vitro and In Vivo Data (Dr. Jingjing Yu)

Dr. Ragueneau-Majlessi will be chairing the session entitled “NDA and Literature Update” on June 30th.

 |  New features

e-PKGene Version 2.0 released April 11th!

The DIDB program is pleased to announce the release of e-PKGene Version 2.0.

Please see this detailed description of the new features.

New features include:

  1. A new responsive design that works on phones and tablets.
  2. A set of new quantitative searches:

    • Users are now able to select a combination of factors (compounds, genes, ethnicities) to query for quantitative measurements. Tabular results are provided in % ∆ from the reference population’s measurements and provide both pharmacokinetic (PK) and pharmacodynamic (PD) data.
    • These results can be further refined by filtering individual columns by text or by a numerical range. Columns can also be reordered or hidden from view. With these tools, users can explore the initial result set and refine the data to their needs. The data then can be saved as a spreadsheet.
  3. New design for displaying full citation and NDA information:

    • For each study, all information has been condensed into a single, easy to understand table. Measurement data for the citation/NDA can be viewed in the same manner as the quantitative results query by clicking on the “% ∆ data” link in the description section.
    • At the top of the citation navigation menu, “PK”, “PD”, and “Side Effects” buttons are highlighted only if the citation contains data for it; one click on either button will hide the information which is not of interest.
      needs. The data then can be saved as a spreadsheet.
  4. Updated drug summaries
 |  News

A new, completely redesigned DIDB is here!

Check out the new DIDB at https://didb.druginteractionsolutions.org

What’s new?

  • Whole new look and feel, but don’t get worried, the workflow remains unchanged. You’ll be able to jump right in.
  • New improved autocompletes to find the compound or therapeutic class you want.
  • You can now select a default compound to use in all DIDB queries.
  • New sortable and searchable query result tables.  Give these a try, you’ll like them.
  • Oh, and this all works on your tablet or phone… well, if your phone is shiny and new.

If a picture is worth a thousand words, a fully functioning website is worth a thousand pictures. Check it out https://didb.druginteractionsolutions.org.

This new version of DIDB went live on November 3rd.

If you have any questions or comments please contact us.

 |  News

DIDB Team to exhibit at the 10th International ISSX Meeting – Toronto 09/29-10/03, 2013

Please visit the DIDB Team at Booth #602 during this year’s 10th International ISSX Meeting to be held in Toronto, Canada September 29 – October 3, 2013.

Also, please come to the following poster presentation:

  • P168 – Analysis of metabolism and transport drug interaction data in new drug applications approved in 2012 (Mulgaonkar A, Ragueneau-Majlessi I, Chung S, Zhang L, and Zhao P)
  • Tuesday, October 1
  • Poster Viewing: 10:30 – 14:00
  • Presented by Authors: 13:30 – 14:00 (Dr. Ragueneau-Majlessi)